PepTalk 2017
PepTalk 2017
Pipeline Two Header

Cambridge Healthtech Institute’s Sixth Annual
Bispecific Antibody Therapeutics
Engineering Multispecificity
January 12-13, 2017 | Hilton San Diego Bayfront | San Diego, CA


Cambridge Healthtech Institute’s Bispecific Antibody Therapeutics conference explores the challenges of engineering multispecificity in order to achieve more effective therapies that bind to at least two molecular targets simultaneously. Next-generation antibody formats are proving fruitful in the efforts to conquer cancer and other diseases. Case studies highlight novel engineering approaches that address safety, stability, enhanced targeting, and manufacturability, as the conference examines current developments and also future directions of these promising molecules.

Preliminary Agenda


ADVANCING BISPECIFICS


KEYNOTE PRESENTATION: BiTE Antibody Constructs for Cancer Therapy

Benno Rattel, Ph.D., Executive Director, Nonclinical Development, AMGEN Research (Munich) Gmbh


Engineered Fab Domains Promote Efficient Production of Bispecific Antibodies in a Single Cell

Christoph Spiess, Ph.D., Senior Scientist, Antibody Engineering, Genentech

 


BISPECIFICS TO FIGHT CANCER

Improving on Cancer Therapy: The Duobody Technology

Paul W.H.I. Parren, Ph.D., Senior Vice President & Scientific Director, Genmab A/S

The Use of Bispecific Antibodies to Modulate Anti-Tumor Immune Responses

Neil D. Brewis, Ph.D., CSO, F-star Biotechnology, Ltd.

A Phase I/II Study of MCLA-128, a Full-Length IgG1 Bispecific Antibody Targeting HER2/HER3, in Patients with Solid Tumors

Mark Throsby, Ph.D., Executive Vice President & CSO, Merus B.V.

 

ENGINEERING & PRODUCTION INNOVATIONS 

Creating Multivalent Bispecific Antibody Forms through Bio-Conjugation

Julie Q. Hang, Ph.D., Senior Scientist, Protein Chemistry, Genentech

Antibody-Based Nucleic Acid Delivery Vehicles

Ulrich Brinkmann, Ph.D., Expert Scientist, Pharma Research & Early Development, Roche Innovation Center Munich

An Efficient Process of Generating Bispecific Antibodies via Controlled Fab-Arm Exchange Using Culture Supernatants

Thomas Nesspor, MS, Scientist, Janssen BioTherapeutics, Janssen Research & Development, LLC

Engineering Next-Generation Biotherapeutics: Developability & Manufacturability

Christopher Smith, Ph.D., Senior Scientific Consultant, Biologics, Genedata

 

 

PLATFORM INNOVATIONS

Tailoring Bispecific DART or Multispecific Trident Formats and Specificities for Different Therapeutic Modalities

Syd Johnson, Ph.D., Vice President, Antibody Engineering, MacroGenics, Inc.

Utilizing the CrossMAb Engineering Platform to Suit Biological Needs

Jörg Thomas Regula, Ph.D., Head, Functional Characterization, pRED Large Molecule Research, Roche Diagnostics GmbH




For questions about the meeting, please contact:

Mary Ruberry
Senior Conference Director
Cambridge Healthtech Institute
Phone: 781-972-5421
Email: mruberry@healthtech.com

For partnering & sponsorship information, please contact:

Companies A-K
Jason Gerardi
Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5452
Fax: 781-972-5470
Email: jgerardi@healthtech.com

Companies L-Z
Carol Dinerstein
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5471
Fax: 781-972-5470
Email: dinerstein@healthtech.com